Program death ligand‐1 immunocytochemistry in lung cancer cytological samples: A systematic review

In this era of personalized medicine, targeted immunotherapies like immune checkpoint inhibitors (ICI) blocking the programmed death‐1 (PD‐1)/program death ligand‐1 (PD‐L1) axis have become an integral part of treating advanced stage non‐small cell lung carcinoma (NSCLC) and many other cancer types....

Descripción completa

Detalles Bibliográficos
Autores principales: Satturwar, Swati, Girolami, Ilaria, Munari, Enrico, Ciompi, Francesco, Eccher, Albino, Pantanowitz, Liron
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2022
Materias:
Timely Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9310737/
https://www.ncbi.nlm.nih.gov/pubmed/35293692
http://dx.doi.org/10.1002/dc.24955

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9310737/
https://www.ncbi.nlm.nih.gov/pubmed/35293692
http://dx.doi.org/10.1002/dc.24955

Ejemplares similares